Neoadjuvant immunotherapy in treatment of oligometastatic locally advanced colon cancer. Clinical case
Open Access
- 13 October 2022
- journal article
- research article
- Published by Publishing House ABV Press in MD-Onco
- Vol. 2 (3) , 21-27
Abstract
Immunotherapy has improved the results of treatment of patients with metastatic colorectal cancer. According to literature, the most cancericidal effect revealed in a microsatellite instability high (MSI-H) tumors. In our case, PD-1/PD-L1/PD-L2 inhibitors (nivolumab) treatment for locally advanced MSI-H colon carcinoma with liver metastasis in 44-year-old patient resulted in tumor regression, so that R0 surgical procedure became possible. Computed tomography scan and pathology report showed complete response, in primary and metastatic tumors. As a result, this allowed to improve the quality of patient’s life.Keywords
This publication has 11 references indexed in Scilit:
- PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal CancerNew England Journal of Medicine, 2022
- Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled OpportunitiesFrontiers in Immunology, 2022
- Neoadjuvant immunotherapy in primary and metastatic colorectal cancerBritish Journal of Surgery, 2021
- Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal CancerThe Oncologist, 2021
- Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study.Journal of Clinical Oncology, 2021
- Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.Journal of Clinical Oncology, 2020
- Neoadjuvant immunotherapy shows promiseNature Reviews Clinical Oncology, 2020
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancersNature Medicine, 2020
- Preoperative nivolumab in patients(pts) with locally advanced colon cancer (T3 or T4): A window-of-opportunity study (NICOLE)Annals of Oncology, 2018
- Predictors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal CancerAnnals of Surgical Oncology, 2015